MedWatch

Sonova downgrades, blames high costs and weak results from key markets

The hearing aid giant now expects revenue growth of 15-19% measured in local currencies, compared to a previous 17-21%.

Photo: Sonova / PR

The developments on certain key markets have been weaker than expected for the world’s largest hearing aid manufacturer, Sonova, in the first few months of its 2022/23 accounting year.

This has led the firm to downgrade its full-year expectations.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs